Literature DB >> 22526021

Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.

Michael P Hart1, Johannes Brettschneider, Virginia M Y Lee, John Q Trojanowski, Aaron D Gitler.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, adult-onset neurodegenerative disease characterized by degeneration of motor neurons, resulting in paralysis and death. A pathological hallmark of the degenerating motor neurons in most ALS patients is the presence of cytoplasmic inclusions containing the protein TDP-43. The morphology and type of TDP-43 pathological inclusions is variable and can range from large round Lewy body-like inclusions to filamentous skein-like inclusions. The clinical significance of this variable pathology is unclear. Intermediate-length polyglutamine (polyQ) expansions in ataxin 2 were recently identified as a genetic risk factor for ALS. Here we have analyzed TDP-43 pathology in a series of ALS cases with or without ataxin 2 intermediate-length polyQ expansions. The motor neurons of ALS cases harboring ataxin 2 polyQ expansions (n = 6) contained primarily skein-like or filamentous TDP-43 pathology and only rarely, if ever, contained large round inclusions, whereas the ALS cases without ataxin 2 polyQ expansions (n = 13) contained abundant large round and skein-like TDP-43 pathology. The paucity of large round TDP-43 inclusions in ALS cases with ataxin 2 polyQ expansions suggests a distinct pathological subtype of ALS and highlights the possibility for distinct pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526021      PMCID: PMC3543833          DOI: 10.1007/s00401-012-0985-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  55 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Neurodegeneration: An expansion in ALS genetics.

Authors:  Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

3.  Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness.

Authors:  Felix Geser; John L Robinson; Joseph A Malunda; Sharon X Xie; Chris M Clark; Linda K Kwong; Paul J Moberg; Erika M Moore; Vivianna M Van Deerlin; Virginia M-Y Lee; Steven E Arnold; John Q Trojanowski
Journal:  Arch Neurol       Date:  2010-10

Review 4.  Genetic causes of frontotemporal degeneration.

Authors:  Tricia M See; Amanda K LaMarre; Suzee E Lee; Bruce L Miller
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-10-11       Impact factor: 2.680

5.  FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis.

Authors:  Ian P Blair; Kelly L Williams; Sadaf T Warraich; Jennifer C Durnall; Annora D Thoeng; Jim Manavis; Peter C Blumbergs; Steve Vucic; Matthew C Kiernan; Garth A Nicholson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-03       Impact factor: 10.154

6.  Clinical and pathological continuum of multisystem TDP-43 proteinopathies.

Authors:  Felix Geser; Maria Martinez-Lage; John Robinson; Kunihiro Uryu; Manuela Neumann; Nicholas J Brandmeir; Sharon X Xie; Linda K Kwong; Lauren Elman; Leo McCluskey; Chris M Clark; Joe Malunda; Bruce L Miller; Earl A Zimmerman; Jiang Qian; Vivianna Van Deerlin; Murray Grossman; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2009-02

7.  TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.

Authors:  Brian S Johnson; David Snead; Jonathan J Lee; J Michael McCaffery; James Shorter; Aaron D Gitler
Journal:  J Biol Chem       Date:  2009-05-22       Impact factor: 5.157

Review 8.  Rethinking ALS: the FUS about TDP-43.

Authors:  Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Cell       Date:  2009-03-20       Impact factor: 41.582

9.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Authors:  Andrew C Elden; Hyung-Jun Kim; Michael P Hart; Alice S Chen-Plotkin; Brian S Johnson; Xiaodong Fang; Maria Armakola; Felix Geser; Robert Greene; Min Min Lu; Arun Padmanabhan; Dana Clay-Falcone; Leo McCluskey; Lauren Elman; Denise Juhr; Peter J Gruber; Udo Rüb; Georg Auburger; John Q Trojanowski; Virginia M-Y Lee; Vivianna M Van Deerlin; Nancy M Bonini; Aaron D Gitler
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

10.  Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.

Authors:  Caroline Vance; Boris Rogelj; Tibor Hortobágyi; Kurt J De Vos; Agnes Lumi Nishimura; Jemeen Sreedharan; Xun Hu; Bradley Smith; Deborah Ruddy; Paul Wright; Jeban Ganesalingam; Kelly L Williams; Vineeta Tripathi; Safa Al-Saraj; Ammar Al-Chalabi; P Nigel Leigh; Ian P Blair; Garth Nicholson; Jackie de Belleroche; Jean-Marc Gallo; Christopher C Miller; Christopher E Shaw
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

View more
  18 in total

1.  Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.

Authors:  Sirinan Tazen; Karla Figueroa; Justin Y Kwan; Jill Goldman; Ann Hunt; Jacinda Sampson; Laurie Gutmann; Stefan M Pulst; Hiroshi Mitsumoto; Sheng-Han Kuo
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 2.  Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

Authors:  Lin Guo; James Shorter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 3.  Dynamic droplets: the role of cytoplasmic inclusions in stress, function, and disease.

Authors:  Triana Amen; Daniel Kaganovich
Journal:  Cell Mol Life Sci       Date:  2014-10-05       Impact factor: 9.261

4.  Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.

Authors:  Leeanne McGurk; Virginia M Lee; John Q Trojanowksi; Vivianna M Van Deerlin; Edward B Lee; Nancy M Bonini
Journal:  J Neuropathol Exp Neurol       Date:  2014-09       Impact factor: 3.685

5.  ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.

Authors:  Michael P Hart; Aaron D Gitler
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

6.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.

Authors:  David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-12-31       Impact factor: 17.088

Review 7.  The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Vladimir N Uversky
Journal:  Autophagy       Date:  2017-12-17       Impact factor: 16.016

Review 8.  Engineering enhanced protein disaggregases for neurodegenerative disease.

Authors:  Meredith E Jackrel; James Shorter
Journal:  Prion       Date:  2015       Impact factor: 3.931

9.  Amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions represent an ER quality control compartment.

Authors:  Marijn Kuijpers; Vera van Dis; Elize D Haasdijk; Martin Harterink; Karin Vocking; Jan A Post; Wiep Scheper; Casper C Hoogenraad; Dick Jaarsma
Journal:  Acta Neuropathol Commun       Date:  2013-06-12       Impact factor: 7.801

10.  De novo mutations in ataxin-2 gene and ALS risk.

Authors:  José Miguel Laffita-Mesa; Jorge Michel Rodríguez Pupo; Raciel Moreno Sera; Yaimee Vázquez Mojena; Vivian Kourí; Leonides Laguna-Salvia; Michael Martínez-Godales; José A Valdevila Figueira; Peter O Bauer; Roberto Rodríguez-Labrada; Yanetza González Zaldívar; Martin Paucar; Per Svenningsson; Luís Velázquez Pérez
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.